In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7.

Mov Disord 2015 Apr 15;30(5):662-70. Epub 2015 Mar 15.

INSERM U 1127, Sorbonne Universités, UPMC Univ Paris Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.

Spinocerebellar ataxias (SCAs) belong to polyglutamine repeat disorders and are characterized by a predominant atrophy of the cerebellum and the pons. Proton magnetic resonance spectroscopy ((1) H MRS) using an optimized semiadiabatic localization by adiabatic selective refocusing (semi-LASER) protocol was performed at 3 T to determine metabolite concentrations in the cerebellar vermis and pons of a cohort of patients with SCA1 (n=16), SCA2 (n=12), SCA3 (n=21), and SCA7 (n=12) and healthy controls (n=33). Compared with controls, patients displayed lower total N-acetylaspartate and, to a lesser extent, lower glutamate, reflecting neuronal loss/dysfunction, whereas the glial marker, myoinositol (myo-Ins), was elevated. Patients also showed higher total creatine as reported in Huntington's disease, another polyglutamine repeat disorder. A strong correlation was found between the Scale for the Assessment and Rating of Ataxia and the neurometabolites in both affected regions of patients. Principal component analyses confirmed that neuronal metabolites (total N-acetylaspartate and glutamate) were inversely correlated in the vermis and the pons to glial (myo-Ins) and energetic (total creatine) metabolites, as well as to disease severity (motor scales). Neurochemical plots with selected metabolites also allowed the separation of SCA2 and SCA3 from controls. The neurometabolic profiles detected in patients underlie cell-specific changes in neuronal and astrocytic compartments that cannot be assessed by other neuroimaging modalities. The inverse correlation between metabolites from these two compartments suggests a metabolic attempt to compensate for neuronal damage in SCAs. Because these biomarkers reflect dynamic aspects of cellular metabolism, they are good candidates for proof-of-concept therapeutic trials. © 2015 International Parkinson and Movement Disorder Society.

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397159PMC
April 2015
59 Reads

Publication Analysis

Top Keywords

total creatine
8
vermis pons
8
total n-acetylaspartate
8
polyglutamine repeat
8
patients
6
extent lower
4
lesser extent
4
metabolites allowed
4
allowed separation
4
plots selected
4
n-acetylaspartate lesser
4
selected metabolites
4
lower glutamate
4
neuronal loss/dysfunction
4
motor scales
4
loss/dysfunction glial
4
severity motor
4
scales neurochemical
4
reflecting neuronal
4
neurochemical plots
4

Similar Publications